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CHARACTERIZING THE SOURCE OF NEUTROPHIL ELASTASE AND PROTEINASE
3 CROSS PRESENTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA
Selena Nicole Carmona, B.S.
Advisory Professors: Gheath Al-Atrash, DO, Ph.D./Jeffrey Molldrem, MD
Discovery of tumor-associated antigens is an important step in designing
effective antigen-targeting immunotherapies. PR1 is a nonameric human leukocyte
antigen (HLA)-A2 restricted leukemia-associated antigen derived from serine proteases
neutrophil elastase (NE) and proteinase 3 (P3). NE and P3 are primarily expressed in
cells of myeloid lineage including granulocytes, bone marrow progenitors and myeloid
leukemia. Our lab reported that NE and P3 are cross-presented by antigen presenting
cells (APCs) and solid tumors, a mechanism whereby exogenous antigens are
endocytosed and presented on HLA class I molecules, inducing a cytotoxic T
lymphocyte (CTL)-mediated immune response. Therefore, identifying non-myeloid
tumors capable of PR1 cross-presentation broadens the application of PR1-targeted
immunotherapies, which to date include PR1 peptide vaccine1, PR1 cellular therapy2,3
and 8F4, a T cell receptor (TCR)-like monoclonal antibody (mAb)4,5.
One possible source of NE and P3 in the microenvironment is neutrophil
extracellular traps (NETs). NETs are composed of deoxyribonucleic acid
(DNA)/histones extruded from polymorphonuclear neutrophils (PMNs) abundant in
antimicrobial proteases, including NE and P3. Although a main function of NETs is
elimination of pathogens, seminal studies have demonstrated immune-regulatory
effects of NETs. Thus there lies a great interest in understanding the role of NETs in
modulating adaptive immune system through cross-priming or cross-tolerance in the
setting of anti-tumor immunity. We are specifically interested in possible roles of NETs
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in facilitating NE and P3 cross-presentation by acute lymphoblastic leukemia (ALL) due
to its high abundance in the bone marrow.
The major aim of this study was to validate PR1 as a target in B-ALL. This
hypothesis is based on strong data from our laboratory showing (1) uptake and crosspresentation of NE and P3 by APCs6,7 including B cells, and (2) susceptibility of nonmyeloid tumors to killing by 8F4 and PR1-CTLs (PR1-specific cytotoxic T lymphocytes)
following PR1 cross-presentation6. Knowledge gained will define PR1 as a therapeutic
target and cross-presentation as a mechanism for antigen expression in B-ALL.
My results identify PR1 as a target in B cell-ALL, and identify NETs as a source
of NE and P3 in the tumor microenvironment. These findings implicate the use of PR1targeting immunotherapies as a novel form of treatment in B cell-ALL.
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Chapter One: Introduction
1.1 Leukemia
Leukemia is cancer of the bone marrow and lymphatic system and is defined by
an accumulation of abnormal white blood cells and a lack of normal functionality. The
result is the suppression of the development of healthy hematopoietic cells, and the
production of a high number of immature and abnormal leukocytes. Leukemias can be
broadly categorized into four types: ALL, chronic lymphocytic leukemia (CLL), acute
myeloid leukemia (AML) and chronic myeloid leukemia (CML). There has been major
progress in treatment of CML and CLL, which are generally chronic malignancies with
good prognosis. However, there remains a desperate need for novel therapies for AML
and ALL, especially in relapsed cases, as they are typically more aggressive.

1.1.1 B Cell Lymphoblastic Leukemias
ALL is a B or T cell precursor stage lymphoid malignancy where the differentiation
process is inhibited by genetic alterations and the enhanced survival and proliferation
of malignant cells8. B- cell ALL accounts for approximately 80% of ALL cases, the
other 20% originating from T cell lineage9. Further, it accounts for approximately 80%
of pediatric leukemias making it the most common pediatric hematologic malignancy,
and 20% of adult leukemia cases.
ALL originates from the stem cells in the bone marrow and has the ability to
spread to other areas as the central nervous system, the lymph nodes, the spleen and
the testes. Blasts are produced when malignant cells become leukemic and begin to
multiply uncontrollably. Leukemia lymphoblasts will then grow and survive at a rate
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more efficient than normal cells. It is estimated that a total on 7000 people in the US
were be diagnosed with ALL in 2016 with a median age of diagnosis at 15 and a 5 year
survival rate of 68.1%, based on data from the National Cancer Institute.
ALL can start in either early B or T cells at different stages of maturity. B cell-ALL
has four main subtypes including early pre B-ALL, common, pro B and mature B-ALL.
Many prognostic factors can determine the survival of a patient, including age, initial
white blood cell count, subtype, and presence of a chromosome abnormality, response
to chemotherapy and status of the ALL treatment. Treatment typically occurs in three
phases: induction, consolidation and maintenance. Total treatment is approximately 2
years long and treatment intensity depends on the subtype of ALL and previously
mentioned prognostic factors. Though most ALL cases occur in children, four out of five
deaths from ALL occur in adults indicative of a better prognosis in children. This
difference occurs because children respond better to treatment, either due to a
difference in the disease itself or because children are able to withstand more
aggressive treatment.
The current treatment for ALL is Hyper-CVAD, a regimen that includes
cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride and dexamethasone.
Cyclophosphamide is an alkylating agent that is most active in the resting phase of
cells, and is therefore cell cycle non-specific. Vincristine sulfate is a plant alkaloid that
is cell cycle specific. It is an agent that inhibits the microtubule structure within the cell,
resulting in cell death. Doxorubicin hydrochloride intercalates between base pairs in the
DNA helix, preventing DNA replication and inhibiting protein synthesis. Dexamethasone
is an anti-inflammatory medication classified as a corticosteroid that is used to
decrease swelling associated with tumors of the spine and brain. Although 80% of
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patients respond to initial therapy, a number of patients fail to respond or relapse and
are offered allogeneic stem cell transplantation. This is the only current curative
treatment for relapsed and aggressive forms of ALL, highlighting the role of the immune
system in eliminating ALL and the need to further develop therapies, which is the
subject of my research. 	
  

1.1.2 Allogeneic Stem Cell Transplantation in Leukemia
Although my work focuses on B-ALL, the foundation for the immunotherapy that
I have studied, i.e. PR1-targeting immunotherapy was initially based on targeting
myeloid leukemia. The two main types of myeloid leukemia include chronic (CML) and
acute (AML). CML is characterized by the accumulation of a high number of mature
myeloid cells in the bone marrow while AML is characterized by the accumulation of
immature blasts in the bone marrow, and has a much more aggressive course of
treatment than CML.
Since the advent of tyrosine kinase inhibitors, CML has been rendered as a
chronic disease in the majority of cases, with a 5-year survival of 65%, while the
prognosis of AML remains dismal with a 5-year survival rate of 27%. However, there
are very few effective treatment options for AML. Current forms of treatment include
chemotherapy and allogeneic stem cell transplantation, a robust form of
immunotherapy that is offered to myeloid leukemia patients who have poor prognostic
factors. In fact, myeloid leukemias are the quintessential immunotherapy-sensitive
tumors, as indicated by the cures that are achieved following allogeneic (allo)
hematopoietic stem cell transplantation (HSCT) 10. Although allo-HSCT replenishes the
hematopoietic components that are ablated following pre-allo-HSCT
chemotherapy/radiation that the patient receives, donor derived T cells within the allo	
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HSCT graft provide a potent immune response that targets the leukemia cells, hence
providing the immunotherapeutic effect of the graft. However, allo-HSCT is associated
with high toxicity and frequent occurrence of graft versus host disease (GvHD). This
occurs in approximately 70% of patients making GvHD the leading cause of treatmentrelated mortality following allo-HSCT 11.
Targeting individual antigens for immunotherapy has shown promising effects on
tumor growth with less toxicity compared to allo-HSCT12. This approach facilitates the
elimination of malignant clones through the graft versus leukemia (GvL) effect while
sparing normal tissue from the off-target effects of GvHD. One approach is to identify
and target leukemia associated antigens (LAA). Tumor specific antigens have proven
to be quite rare. However, a related concept involves targeting LAA. Derived from
proteins expressed in normal tissue, they have an increased/aberrant expression in
leukemia. Studies in our lab have identified the LAA PR1, a nonameric peptide derived
from NE and P3, which will be discussed in detail in the following section.

1.1.3 NE, P3, and PR1
NE and P3 are serine proteases stored in neutrophil cytoplasmic azurophilic
granules. Located on the terminal region of the short arm of chromosome 19, NE and
P3 transcription occurs during the promyelocytic stage of neutrophil maturation13. Both
play a large role in anti-microbial defense 14 and are endogenously expressed in
granulocytes, monocytes, mast cells, and bone marrow myeloid progenitors. Both are
also aberrantly expressed in AML and CML15-17. Serine proteases function to digest
and clear phagocytosed antigens in PMNs13. Although much of their cytotoxic function
occurs within the neutrophil, NE and P3 are capable of being secreted once neutrophils
are activated at sites of inflammation. Inflammatory stimulation initiates the
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translocation of neutrophil granules to the plasma membrane wherein their contents are
released into the microenvironment 13. A portion remains bound to the PMN membrane
in their active form so that chemokine, cytokine, growth factor and cell surface receptor
functions can be regulated by both soluble and membrane-bound protease 13. Further,
one of many extracellular functions includes activating lymphocytes and the cleaving of
adhesion molecules 13. All of these functions identified the role of NE and P3 in both
pro- and anti-inflammatory activities along with the effect on various immune responses
at sire of inflammation.
P3 has been associated with autoimmune diseases, including vasculitis and
rheumatoid arthritis, when expressed on the neutrophil surface. Further, P3 is a target
of antineutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis
(GPA); formally know as Wegener granulomatosis, which is found in more than 80% of
GPA patients. This is caused by P3 secretion from neutrophils that favors the
development and progression of chronic inflammatory diseases. Although P3 had been
identified in the aforementioned autoimmune diseases, it was important to determine
how autoreactivity to antigens was initiated and whether the targeted autoantigens, in
this case P3, played a role in the reversal of tolerance. Ludewig et al. identified that
DCs in animal models played an important role in initiating and maintaining immune
responses to self-antigen in autoimmune disease18. Therefore, Csernok et al.
investigated the effect of P3 on immature DCs in patients with GPA, Crohns disease,
and other granulomatous diseases19. They reported that P3 induced DC maturation
through induction of protease-activated receptor (PAR)-2 expression on immature DCs,
and PAR-2 cleavage and activation. This was hypothesized based on data identifying
the contribution of PAR expression to inflammation, high expression on DCs, and
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activation of epithelial cells through PAR binding to P3. The cleaving of PAR-2 by P3
resulted in the induction of DCs to become functional APCs through up-regulation of
CD83, CD86, CD83 and HLA-DR surface expression, along with the down-regulation of
CD14, a molecule expressed by immature DCs. Mature DCs exposed to P3 acquired
the ability to stimulate P3-specific CD4+ T cells, which produced IFN and had a Th1
phenotype. Expression of IFN favors the development of a granulomatosis
inflammation as seen in GPA. This characterizes the role of P3 and PAR-2 in the
induction of adaptive immunity and the reversal of tolerance in P3-targeting
autoimmunity.
Derived from NE and P3, PR1 is a nonameric HLA-A2 restricted peptide.
Immunity against PR1 was demonstrated in 2000 when our lab identified the
importance of PR1 peptide in CTL immune responses against CML 17. Data identified
the importance of targeting PR1 based its role in remission post transplant.
The identification of tumor associated antigens, such as PR1, and the design of
tetramers to identify peptide/MHC allows the ability to detect tumor antigen-specific T
cell responses. CTLs identified that selectively target PR1 have been shown to be
elevated in myeloid leukemia patients 7 and have cytotoxic function against malignant
cells along with the inhibition of progenitor cell growth 20,21. Their cytotoxic function has
also been shown to greatly contribute to cytogenetic and molecular remission of CML
patients treated with interferon-alpha or allogeneic stem cell transplant17. This
suggested that interferon treatment induced remission through the expansion of
autologous PR1-CTLs 17. A possible mechanism of action was identified as the up
regulation of MHC class I or tumor antigen on malignant cells resulting in a robust CTL
response 17. A second method of action includes the strong GvL effect post transplant
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so that allogeneic CTL target self-peptide on malignant cells 17. The successful killing of
chronic and acute myeloid leukemia cells by PR1-CTLs supports the targeting of
surface PR1-CTLs to elicit an immune response and the boosting of anti-leukemia
responses.
As previously described, the GvL effect following allogeneic stem-cell
transplantation was quite robust in eliminating malignant cells. Therefore, identifying a
form of treatment that boosts immunity against PR1 may prove to be beneficial for
treatment of myeloid leukemias. A peptide vaccine was identified to induce and
enhance leukemia-specific T cell responses to PR122. This response was robust due to
a higher frequency of PR1-specific CD8+ T cells with a memory phenotype in patients
with leukemia in comparison to healthy individuals 17,21,23. Studies also showed that
post vaccine administration there was a reduction in leukemia burden indicative of an
immune response against MDS and leukemia 22. These results validated targeting of
endogenous peptides, such as PR1, with various forms of immunotherapy including
vaccination and adoptive cell therapy in combination with current forms of treatment.
A newer form of treatment against tumor-specific antigens includes monoclonal
antibodies (mAb). mAb used in clinical settings target surface proteins that are
expressed on normal cells yet are overexpressed in malignant cells 4,5 and have an
increased effectiveness due to the ease and ability of frequent dosage. A mAb
engineered in our lab called 8F4 will be discussed in the subsequent section.

1.1.4 8F4
The significance of PR1-targeting immunotherapy was highlighted through two
main observations: PR1-CTLs contributed to remission in myeloid leukemia patients
treated with interferon and allogeneic stem cell transplant 17,24, and PR1 vaccination
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induced a robust CD8 response in myeloid malignancies 1,25. However, because tumor
burden is a limiting step in immunotherapy, our group developed an anti-PR1/HLA-A2
mAb, 8F4, that can overcome high disease burden through repeat high-dose
administration4. There also exists a need to target chemo-resistant leukemia stem cells
(LSC) as relapse rates are quite high. A therapeutic advantage of TCR-like mAb
includes the increased affinity binding to surface peptide/MHC complexes 26-30
compared to the very low affinity of a TCR 31,32. 8F4 is a TCR-like IgG2a mAb that
binds the combined epitope of the PR1/HLA-A2 with very high affinity4. Studies showed
that 8F4 has success in mediating complement-dependent cytolysis (CDC) of AML but
not normal leukocytes. Further data showed the inhibition in the growth of AML
progenitor cells, and the lysis of LSC, but no effect on normal progenitors from healthy
donors 4. Further 8F4 reduced tumor burden in relapsed, refractory, and secondary
AML identifying its efficacy in aggressive forms of leukemia 5.
Despite success in current treatment in inducing remission, relapse rates are
quite high. This is attributed to LSC that are not affected by chemotherapy. Therefore,
the ability of 8F4 to induce lysis of LSCs and secondary AML warrants the broadening
of TCR-like antibody development to target other leukemia-associated peptide/MHC
complexes.

1.2 Antigen Presentation
The biggest hurdle for developing effective immunotherapies is in identifying
tumor antigen. To induce a T cell response against antigen, the target cell must
express it. MHC class I molecules, expressed on nearly all somatic cells, typically bind
intracellular peptides and are recognized by CD8 T cells inducing a cytotoxic response
when expressed on the cell surface. This process begins when proteins are degraded
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via cytosolic and nuclear proteins and result in peptides approximately 8-16 amino
acids long. Peptides are then bound to the MHC class I molecule forming a stable
complex. Once this occurs, peptide/MHC-I is transported to the cell surface wherein
CD8 T cells will recognize the peptide complex through its TCR. Then with secondary
signaling from co-stimulatory and co-inhibitory receptors, T cells are activated and lyse
the target cell. MHC class II antigen presentation on the other hand includes the uptake
of exogenous antigen and is therein recognized by CD4 helper T cells on the cell
surface of APC, specifically dendritic cells (DCs) or B cells. MHC class I is involved in
eliciting cytotoxic T cell response whereas MHC call II antigen presentation is involved
in CD4 helper T cell and B cell response.
Cross-presentation is another mechanism that activates naïve CD8 T cells
targeting extracellular antigens. Through this mechanism, antigens are taken up and
presented on MHC class I molecules to elicit a CD8 T cell response 33. Most studies to
date in which cross-presentation of tumor derived antigen occurs focused on APCs,
and the ability of tumors to evade the immune system through the down regulation of
antigen presentation34. However, a more recent study identified the ability of nonAPCs, in this case mesenchymal stromal cells, to cross-present tumor antigen 35
highlighting the importance of antigen cross-presentation in eliciting anti-tumor
immunity.
As previously mentioned, PR1 is targeted in myeloid leukemia through PR1
vaccine 1,25, PR1-CTLs17,20, and 8F4 mAb 4,5. We broadened this to other tumors, such
as breast cancer, that can have monocytic and neutrophilic infiltration, and therefore
the presence of NE and P3. Although NE and P3 are primarily expressed in
hematopoietic cells of the myeloid lineage, studies reported NE and P3 in breast
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cancer tissue 36-38. The source of NE was unknown but endogenous expression was
identified in breast cancer cells 39,40. We were unable to confirm endogenous
expression in breast cancer cell lines ourselves, so we hypothesized that intracellular
expression of NE and P3 in breast cancer was due to uptake. Because some breast
cancer subtypes are known to have PMN and monocyte infiltrations 41 that release NE
and P3 into the microenvironment, our lab tested whether PMNs serve as a source of
NE and P3 uptake in breast cancer. Our lab confirmed uptake of both soluble and
PMN-associated NE and P3 in breast cancer cell lines that lack endogenous NE and
P3 with increasing uptake over time 6,42. After uptake, PR1, a peptide derived from NE
and P3, was shown to be cross-presented in HLA-A2+ breast cancer cells lines
following NE and P3 uptake at 24 hours 6,42. Because PR1 can be successfully
targeted in myeloid leukemias, our lab confirmed the broadening of PR1-targeted
therapies by identifying the killing of breast cancer cell lines after PR1 crosspresentation by PR1-CTLs and 8F4 Ab 6,42. This phenomenon was further shown in
lung cancer, a tumor also characterized by possible neutrophilic and monocytic
infiltration 43. Our study provided evidence that cross-presentation is a novel
mechanism whereby hematopoietic antigens are expressed on solid tumors.
Previous studies from our lab have also shown that normal and leukemic APCs,
including B cells, cross-present PR17. This was the basis of my thesis in studying the
ability of B-ALL to cross-present PR1. This hypothesis is furthered strengthened by the
location of B-ALL in the bone marrow, as this is an area rich in NE and P3. The bone
marrow is also present with inflammatory cells such as PMNs and monocytes, cells that
routinely secrete NE and P3. This set the basis of my project in further identifying the
susceptibility of non-myeloid tumors to killing by PR1-targeting immunotherapies.
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Although neutrophils are abundant in the microenvironment and infiltrate various
tumor types, the mechanism of NE and P3 uptake by tumor cells remains poorly
understood. NETs, abundant in NE and P3, are the result of a unique form of cell death
that allows neutrophil granule contents to be released into the microenvironment. We
therefore hypothesized that NETs serve as a possible source of protease uptake. This
will be discussed further in the subsequent section.

1.3 NETs, abundant in NE and P3, serve as a possible source in the
tumor microenvironment
NE and P3, proteases secreted by PMNs in the microenvironment, have an
additional extracellular mechanism by which they have antimicrobial effects13. This
cytotoxic effect lies in the formation of NETs: DNA secreted by activated neutrophils
abundant in histones and various neutrophil serine proteases. NETs, a result of a
unique form of neutrophil-programmed cell death, are characterized by a loss of
intracellular membranes followed by the rupture of the cytoplasmic membrane. As
previously mentioned, NETs are composed of DNA, histones, and various antimicrobial
proteases, including NE, P3, myeloperoxidase (MPO), Cathepsin G, and various
others. This form of cell death is independent of apoptosis and necrosis but is still
considered a form of antimicrobial cell death44.
Previous studies showed that PMNs, and more specifically NETs, have a large
role in anticancer immunity and autoimmunity, specifically, in patients with ANCArelated autoimmunity and systemic lupus erythematosus (SLE) 45. Sangaletti et al.
confirmed a direct correlation among the formation of NETs and the production of
ANCA, which target neutrophilic intracellular proteins MPO and P3. Therefore, the
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break in tolerance toward neutrophilic cytoplasmic proteins implied their necessary
availability in the microenvironment to be presented on the surface of APCs for
recognition 45. This identified apoptotic neutrophils as a source of neutrophil auto
antigens. However, in PMNs undergoing necrosis, cytoplasmic granules undergo
structural changes that alter MPO and P3 epitope confirmation making them unable to
be cross-presented by APCs45. On the other hand, in NETosing PMNs, cytoplasmic
proteins are associated with nucleic acid and histones maintaining their conformation,
their antimicrobial function and the ability to be cross-presented 45. In this study, data
confirmed that NETs have the ability to transfer neutrophil cytoplasmic proteins to
mDCs resulting in cross-presentation that trigger an adaptive immune response as
indicated by ANCA production. In identifying the ability of NETs to serve as a source of
cytoplasmic neutrophilic proteins that are enzymatically active in the microenvironment,
we therefore hypothesized that NETs are capable of transferring NE and P3 to B-ALL
cell lines inducing PR1 cross-presentation.

1.4 Project Summary and Hypothesis
Due to our success in PR1 targeting on myeloid leukemia and solid tumors, the
presence of NE and P3 in the bone marrow microenvironment and the ability of APCs,
including B cells, to cross-present PR1, we hypothesized that the lymphoid malignancy
B-ALL takes up and cross presents NE and P3 from the bone marrow
microenvironment. This further broadens the use of accepted PR1 targeting therapies
including PR1-CTLs, PR1 vaccine and 8F4 mAb, to tumors with possible neutrophilic
and monocytic infiltration.
In this study, we evaluated whether 1) B-ALL cell lines cross-present PR1; 2)
whether PR1-targeting immunotherapies effective target B-cell ALL; and 3) whether
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NETs are a source of NE and P3 uptake. We provided data that ALL cell lines take up
soluble and PMN-associated NE and P3, and cross-present PR1 from both sources.
Further, we confirmed NETs serve as a source of NE and P3 uptake, however are not
as efficient as resting PMNs as a source. Together our data demonstrated PR1 crosspresentation in B cell ALL and its targeting by PR1-CTLs.
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Chapter 2: Materials and Methods
2.1 Cell Lines
Healthy-donor peripheral blood mononuclear cells (PBMC) and PMN were
isolated from buffy coats obtained from Gulf Coast Blood Bank by single or double
Ficoll gradient using Histopaque-1077 and Histopaque-1119 (Sigma Aldrich). SupB15
(B lymphoblast leukemia), SB (B lymphoblast leukemia), and T2 (B cell/T cell
hybridoma) cell lines were obtained from American Type Culture Collection (ATCC).
RS4 (B lymphoblastic leukemia) and Nalm6 (B lymphoblastic leukemia) cell lines were
kindly provided by Dr. Dean Lee (Ohio State University). Cells were cultured in RPMI
1640 media with 2.5 mM l-glutamine (Hyclone) supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100 µg/mL streptavidin (Invitrogen). All cells were
grown in a humidified incubator set at 37 °C and 5% CO2. Cells lines were validated at
the MD Anderson Sequencing and Microarray Facility using short tandem repeat DNA
fingerprinting and checked for mycoplasma on a routine basis via PCR (PromoKine).
Surface phenotype of each cell line was determined by flow cytometry. Standard B-cell
markers (anti-human-CD19-PE, anti-human CD10-BV421, anti-human C34-Pe/Cy7,
anti-human CD38-AF700 antibodies all obtained from BioLegend) were incubated with
cells at a 1:50 dilution for 30 minutes on ice. Phenotype of each cell line is listed below
in Table 1
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Table 1: B-ALL Cell Line Phenotype

	
  

Cell Line

CD19

CD34

CD10

CD38

RS4

Positive

Negative

Negative

Positive

SB

Positive

Negative

Negative

Positive

Supb15

Positive

Positive

Positive

Negative

Nalm6

Positive

Positive

Negative

Negative
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2.2 HLA-A2 Transduction
HLA-A2*0201 transfection was done using lentiviral vectors as previously
described 46. The first step included packaging the lentivirus with the use of 293METR
cells. The 239METR cells were thawed and grown in dMEM media (HyClone) with 10%
fetal bovine serum (FBS) (Gemini Bio-Products, Sacramento, CA, USA) to 90%
confluency in a T150 flask. Cells are then seeded in a T150 flask at 4.5x106 cells per
total volume forty-eight hours prior to transfection or 1.125x107 cells twenty-four hours
prior transfection. Viruses were collected 48 hours and 72 hours after transfection.
Each transfection reaction requires 2 µg VSV g plasmid, 4.7 µg pCMV R8.2 or R8.91
plasmid and 2.3 µg Lentiviral vector. In a 15 mL tube, the plasmid, pCMV R8.9 and
Lentiviral vector were combined in 4.5 mL of Opti-MEM media and incubated at room
temperature for 5 minutes. In a second 15 mL tube, 90 μL LipofectAmine 2000 and 4.5
mL of Opti-MEM media (Gibco) were combined and incubated at similar incubation
conditions. Tubes 1 and 2 were then combined and incubated at room temperature for
30 minutes.
In T150 flasks with confluent 293-METR cells, 6 mL of Opti-MEM media were
added along with the 9 mL of Tube 1 and 2. Five hours post transfection, the virus was
aspirated and fresh 20 mL dMEM with 10% FBS was added to the cells and placed
back in the incubator at 37 °C and 5% CO2. After overnight incubation, media was
aspirated, discarded, and replaced with 20 mL fresh dMEM media with 10% FBS. Cells
were placed back in incubator for another overnight incubation period. Forty-eight
hours post transfection, media was harvested and replaced a second time with fresh
dMEM media with 10% FBS. Harvested media was stored at 4°C. This process was
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repeated 72 hours post transfection in a similar manner. If needed, packaged viral
vectors can be concentrated.
Once the amount of virus to be added was determined, B-ALL cell lines were
plated in 6-well plated and allowed to grow to about 70% confluency. Two
concentrations of virus were added to cells to determine the successful transduction
efficiency. On the day of transduction, viral stock, 2 µL 4 mg/mL polybrane and 1 mL
IMDM (ATCC) were combined and added to the cells in a 6-well plate. The 6-well
plates were centrifuged at 2500 rpm for 100 minutes at 32 °C. Twenty-four hours post
transduction, 1 mL of fresh media was added to samples in the 6-well plate to reduce
any possibility of cell death. Forty-eight hours post transduction, the transduction
protocol was repeated, and the cells allowed to rest for an additional 24 hours. Ninetysix hours post transduction, cells were surface stained with anti-human HLA-A2
(BB7.2)-FITC antibody and sorted for HLA-A2+ (FITC+) cells using FACSAria IIIu #1
Cell Sorter (BD). Cells were re-sorted once a month to ensure that cells not
successfully transduced would not overcome the culture and give false results in
experiments.

2.3 Generation of Protein Lysates and Western Blots
Approximately 2x106 cells were lysed in 50 µL of RIPA lysis buffer 1X with
protease inhibitor (Santa Cruz Biotechnology) (ten µL of protease inhibitor were added
to 1 mL of RIPA buffer), and then rotated at 4 °C for 30 minutes. Protein concentration
was measured by a Bradford assay. The volume of each protein lysate used was
dependent on the protein concentration, but approximately 20 µg of total protein was
alliquoted. Five microliters of loading dye was added to each sample, then vortexed,
spun down, and boiled for ten minutes to denature the proteins for SDS-PAGE.
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Whole cell lysates were separated by electrophoresis on a 10% SDS gel
(BioRad), and transferred to a polyvinylidene difluoride (PVDF) membrane. The
membrane was blocked in 5% milk in TBS-TWEEN for 1 hour at room temperature.
Primary antibody was added to blocking buffer at the proper dilution and allowed to
rotate with the membrane overnight at 4 °C. Membrane was then washed with 0.05%
TBS-TWEEN 3x for 8 minutes each. The blot was then incubated with the appropriate
secondary antibody in 5% milk blocking buffer at room temperature for 1 hour with
rotation. Membranes were then washed with 0.05% TBS-TWEEN 3 times for 8 minutes
each wash. Antibodies used included mouse anti-NE, clone NP57 (Santa Cruz
Biotechnology), anti-P3, clone MFPR3-2 (ThermoFisher Scientific) and mouse antiactin, Clone C4 (Millipore). During final wash, an ECL reagent mixture was prepared.
The reagent is BioRad Clarity at a 1:1 mixture with 7 mL total for each blot. ECL
reagent was added to the blot and incubated at room temperature for 5 minutes. The
blot was then imaged using ChemiDoc Touch Imaging System (BioRad).

2.4 RNA Purification and RT-PCR
To purify RNA, the RNeasy Plus Mini Kit (Qiagen) was used per manufacturers
instructions. 10x107 tumor cells were harvested and 600 µL of Buffer RLT with betamercapotoethanol (B-ME) and vortexed for 30 seconds. Solution was transferred to a
gDNA Eliminator spin column and placed into a 2 mL collection tube. Samples are
centrifuged for 30 seconds at 8000g and the column in discarded while the flow through
is kept. Six hundred microliters of 70% ethanol is added to the flow-through and mixed
well with a pipette. Seven hundred microliters of the samples is then added to an
RNeasy spin column, placed in a 2 mL collection tube, and centrifuged for 15 seconds
at 8000g. The flow-through in this case is discarded and the filter is kept. Five hundred
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microliters of Buffer RPE is added to the RNeasy spin column and centrifuged for 15
seconds at 8000g. Five hundred microliters of Buffer RPE is added again to the
RNeasy spin column and this time centrifuged for 2 minutes at 8000g. The spin column
is then placed into a 1.5 mL eppendorf tube and 30-50 µL of RNase-free water is
directly added to the spin column membrane. The RNA is eluted by a last centrifugation
step of 1 minute at 8000g. The concentration of the sample is read on a
Synthesis of cDNA was performed using the Gene Amp RNA kit (PerkinElmer). The
following primers were ordered from Sigma-Aldrich: ELANE (forward 5’CACGGAGGGGGAGAGACC-3’; reverse 5’-TATTGTGCCAGATGCTGGAG-3’) and
PRTN3 (forward 5’-GACCCCACCATGGCTCAC -3; reverse 5’ATGGGAAGGACAGACAGGAG-3’). ACTIN (forward 5’CCAGAGCAAGAGAGCTATCC-3’; reverse 5’-CTGTGGTGGTGAAGCTGTAG-3’)
served as a loading control. Following denaturation for 5 minutes at 95 °C, samples
were amplified for 35 cycles using an iCycler iQ thermal cycler (Bio-Rad Laboratories).
Samples were run on a 1.5% agarose gel and bands were imaged using GelDoc2000
(Bio-Rad Laboratories) and analyzed by Quantity One software (Bio-Rad Laboratories).

2.5 NE and P3 uptake in B-ALL cell lines
	
  

Analysis of uptake of NE and P3 in B-ALL cell line was carried out by standard

flow cytometry methods. Cells were co-cultured in reduced serum medium (0.5% FBS)
with 10 µg/mL soluble NE (Lee), soluble P3 (Athens), irradiated PMN (7500 cGy), or
resting PMNs at a ratio of 3:1 (PMN: B-ALL cell). After co-incubation, B-ALL cells were
washed in cold phosphate-buffered saline (PBS) (Lonza), and then stained for B-ALL
surface markers along with Live/Dead Fixable Aqua (Tonbo). Cells that were cocultured with healthy PMNs were also cultured with IVIG at 1:10 ratio diluted in PBS.
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Because PMNs are very high in Fc receptor expression, there can be a significant
amount of non-specific binding. Addition of IVIG to the staining process will inhibit this.
After surface staining, cells were washed in PBS, fixed in 1% formaldehyde
(ThermoFisher Scientific) in PBS and permeabilized in 5% Perm/Wash Buffer (BD).
Uptake of NE and P3 was then determined by staining with Anti-NE-AF647 and AntiP3-AF488. Samples were analyzed on the LSRFortessa Analyzer, and analyzed via
Flowjo software (Treestar Ashland OR).

2.6 PR1 Cross-Presentation
To determine PR1 cross-presentation, B-ALL cell lines were co-cultured with 10
µg/mL of soluble NE, soluble P3, and with irradiated (7500 cGy) PMNs at a ratio of 3:1
(irradiated cell: B-ALL cell) in reduced serum media (0.5% FBS). Cells were then
surface stained with B- ALL phenotypic markers (anti-CD19-PE (BioLegend), antiCD34-AF700 (BioLegend), anti-CD38-Pe/Cy7 (BioLegend), anti-CD10-BV421
(BioLegend)) at a 1:50 dilution, Aqua Live Dead (Tonbo) stain at a 1:100 dilution, antihuman 8F4-AF647 (made in house) to identify PR1 cross-presentation at a 1:100
dilution, and finally with anti-human HLA-A2 (BB7.2)-FITC (BioLegend) at a 1:50
dilution, as previously described4. Incubation was for 30 minutes on ice. Cells were
washed once more in cold PBS, and fixed in 1% formaldehyde. T2 cells pulsed with
PR1 and CG1 peptide (Bio-synthesis Inc., Lewisville, TX, USA) were used as a positive
and negative control, respectively. T2 cells are commonly used in studying antigen
recognition by CTLs through administering exogenous antigen where they are bound
and displayed on MHC class I molecules. They are however deficient in a peptide
transporter involved in antigen processing (TAP) and therefore do not transport antigen
to the endoplasmic reticulum (ER)/Golgi apparatus47 to be bound to MHC class I
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molecules. Therefore, when pulsed with a peptide of interest, CTL response can be
determined in a non-competitive environment. When pulsed with PR1, the peptide will
bind to the HLA-A2 molecule on the cell surface and can therefore bind to 8F4
antibody. Samples were collected on a BD LSRFortessa, analyzed on FlowJo software
(Tree Star) and graphed with GraphPad Prism.

2.7 PR1-specific CTLs
To expand PR1-specific CTLs, DCs were matured from adherent monocytes
and then used as professional APCs. Healthy peripheral blood mononuclear cells
(PBMC) isolated from a buffy coat were adhered to a 6 well plate at 37 °C in
Macrophage Serum Free Medium. Lymphocytes from the same donor were separated
and co-cultured with 40 µg/mL of PR1. For five days, cells were then stimulated with
interleukin (IL)-7 (10ng/mL) (rhIl-7, carrier free; BioLegend) and IL-2 (10 ng/mL) (rhIL-2;
R&D) Adhered monocytes were matured into monocyte-derived DC through the
addition of granulocyte macrophage colony-stimulating factor (GM-CSF) (100
ng/mL)(Sanoti), IL-4 (50 ng/mL) (rhIL-4, carrier free; Tonbo Biosciences) and tumor
necrosis factor (TNF)- α (25 ng/mL) (rhTNF- α; BioLegend). After 5 days, DCs were
detached from the 6 well plates, co-cultured with PR1 peptide at 40 μg/mL and
combined with expanded lymphocyte population. The co-culture of mature DCs with
lymphocytes was stimulated once again with IL-7 (10 ng/mL) and IL-2 (25 ng/mL) for an
additional 7 days to induce proliferation. On day 14 of stimulation, cells were harvested
and analyzed via flow cytometry by PR1 dextramer staining to determine the
percentage of antigen-specific cells that were generated.	
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2.8 PR1-CTL Cytotoxicity Assay
A standard cytotoxicity assay was used in determining specific lysis, as
previously described16,17. HLA-A2 positive cells were co-cultured overnight with soluble
NE and P3 (10 µg/mL), washed in RPMI 1640 (HyClone), and resuspended at 1.0 x 105
cells/mL. Cells were then stained with calcein-AM (Invitrogen) at a 1:200 dilution for 15
minutes at 37 °C. Stained cells were then washed three times in RPMI 1640, and
resuspended once again at 2.0 x 105 cells/mL. Ten microliters of stained cells were
added to a Terasaki plate and co-cultured with PR1-specific CTLs at 5 various ratios
(10:1; 5:1; 2.5:1; 1.25:1; 0.625:1 (PR1-CTLS: B-ALL)). Plates were spun at 1500 rpm
for 60 seconds and incubated for four hours at 37 °C in 5% CO2. Wells with target cells
alone and medium alone were used as maximum and minimum fluorescence emission,
respectively. After incubation period, 5 µL of trypan blue was added to each well and a
microplate fluorescence reader then quantified fluorescence. A decrease in the
emission of fluorescence was indicative of a reduced specific lysis as the trypan blue
quenches the hemoglobin contained in the calcein-AM reagent. With values given,
percentage specific lysis was calculated by using the formula:
(1 – [fluorescencetarget + effector – fluorescencemedia]/[fluorescencetarget alone –
fluorescencemedia]) x 100.
T2 cells pulsed with PR1 and CG1 peptide was used as positive and negative controls,
respectively.

2.9 Induction of NET formation and identification via flow cytometry
	
  
PMNs from a healthy donor were derived by an already established density
gradient centrifugation protocol using Histopaque 1077 and 1019. 1x106 PMNs were
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placed in a FACS tube, treated with Ionomycin (4 µM) (Sigma) or Phorbol-1-myristate13-acetate (PMA)(100 nM) (Sigma Aldirch) and incubated for four hours at 37 °C with
5% CO2 in air. Cells were then fixed in 2% formaldehyde, blocked for 30 minutes in 2%
bovine serum albumin in PBS at 37°C, and stained with primary rabbit anti-human
histone H3 antibody (citrulline 2,8,17) (Abcam) at a 1:300 dilution, AF647 goat antirabbit IgG (H+L) secondary antibody (Invitrogen) at a 1:300 dilution and FITCconjugated anti-MPO antibody (BioLegend) at a 1:50 dilution. Each incubation period
was 30 minutes. After every incubation, the samples were washed in PBS with 2% BSA
and then centrifuged at 16,400 rpm at 4 °C for 20 minutes. Lastly, samples were
stained with Hoechst 33342, trihydrochloride trihydrate (Thermo Scientific) in 2% BSA
in PBS at a 1:5000 dilution. Analysis was conducted by flow cytometry. Gating strategy
included first on DAPI positive cells, then on cells positive for H3 citrullination, an early
marker of NETosis, and lastly on MPO positive cells. Cells marked as triple positive
were considered PMNs undergoing NETosis.

2.10 Identification of NETs via confocal microscopy
To perform confocal microscopy, coverslips were first pretreated with 0.001%
poly-L-lysine. Healthy donor neutrophils were treated with PMA (100 nM) or Ionomycin
(4 µM) and then incubated at 37 °C for four hours. NETs were then fixed in 4%
formaldehyde and incubated for 30 minutes at room temperature. Coverslips were
washed in PBS, blocked with 5% donkey serum and 0.5% Triton X in PBS, and
incubated at 4 °C overnight. Coverslips were then stained in anti-MPO-FITC or anti-P3AF488, anti-NE-AF647, and Hoechst. Lastly, coverslips were placed on a slide with
prolong gold without DAPI, and sealed with nail polish. Confocal images to show NET
formation were taken using a Leica Microsystems SP2 SE confocal microscope (Leica)
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with x 10/25 air, x63/1.4 oil objectives and analyzed using Leica LCS software.

2.11 Determine whether NETs are a source of NE and P3 uptake
NET formation was induced in a manner similar to what has been previously
described 48. After a 4-hour incubation at 37 °C, NETs were co-cultured with B-cell ALL
cell lines overnight. At this time point, cells were then stained with fluorescently
conjugated B-cell ALL phenotypic markers along with life/dead aqua, fixed in 1%
formaldehyde and permeabilized in 5% Perm/Wash Buffer (BD) in deionized water.
Once permeabilized, cells were stained with anti-NE-AF647 and anti-P3-AF488 to
determine uptake by flow cytometry. We hypothesized that uptake would occur due to
the presence of NE and P3 localized in the NETs once released into the tumor
microenvironment. The first four conditions listed below are necessary in determining
whether NET-associated NE and P3 are taken up. Intracellular staining in B-ALL cell
lines alone and B-ALL cell lines co-cultured with PMNs were used as a negative and
positive control, respectively. The latter was used as a positive control as we have
already shown PMN-associated NE and P3 uptake occurs in B-ALL cell lines (Figure 67).
1. B-ALL cell line alone (negative control)
2. Resting PMN + B-ALL cell line (positive control)
3. (Ionomycin + PMN (NETs)) + B-ALL cell line
4. (Ionomycin + DNAse + PMN) + B-ALL cell line
Publications have previously shown that the integrity of the DNA backbone in
NETs is necessary to maintain proteolytic activity and conformation of antimicrobial
proteases to promote uptake and mDC activation 45. Therefore, NETs were treated with
DNAse (100 U/mL) (Sigma Aldrich) after inducing NETosis to disrupt the structure of
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the protease/DNA interaction, co-cultured with B-ALL cell lines overnight and stained
for intracellular uptake of NE and P3. It was also important to differentiate between
NET-associated NE and P3 uptake and the effects of Ionomycin and DNAse treatment
on uptake. Therefore, conditions listed below were done to prove that any uptake seen
in ALL co-cultured with NETs was indeed NET-associated NE and P3 uptake.
5. DNAse + PMN + ALL cell line
6. Irradiated PMN + ALL cell line
7. DNAse + Irradiated PMN + ALL cell line
8. Soluble NE/Soluble P3 + ALL cell line
9. Ionomycin + Soluble NE/Soluble P3 + ALL cell line
10. DNAse + Soluble NE/Soluble P3 + ALL cell line
In comparing the efficiency of uptake between possible sources of NE and P3 in
the microenvironment, it was also important to determine the spontaneous ability of
resting and irradiated (7500 cGy) PMNs to undergo NETosis. To achieve this, cells at
each condition were incubated sequentially with primary anti-histone H3 antibody at
1:300 dilution, AF647 goat anti-rabbit IgG (H+L) secondary antibody at 1:300 dilution,
and anti-MPO-FITC antibody at a 1:50 dilution. Each incubation was followed by a
wash with 2% BSA in PBS and centrifuged at 1500 rpm at 4°C for five minutes.
Samples were then resuspended in Hoechst 333342, trihydrochloride, trihydrate at
1:5000 dilution and analyzed via flow cytometry.
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Chapter Three: Results
3.1 B-ALL cell lines cross-present PR1 rendering them susceptible to
killing by PR1-targeting immunotherapy
3.1.1 B-ALL cell lines Lack Intracellular Expression of NE and P3
Because B cell ALL is a non-myeloid malignancy, it is expected to lack
endogenous expression of NE and P3. Therefore, any PR1/HLA-A2 surface expression
was attributed to NE and P3 uptake and PR1 cross-presentation. To confirm lack of
endogenous expression of NE and P3, mRNA expression levels were first confirmed on
public data provided by CCLE (Cancer Cell Line Encyclopedia) and then ALL cell lines
were analyzed via RT-PCR, western blot, and flow cytometry. Lack of endogenous NE
and P3 expression was confirmed in the panel of B-ALL cell lines, in agreement with
publically available data from the Cancer Cell Line Encyclopedia (CCLE) (Figure
1A/Figure 2A). Based on RT-PCR conducted, when compared to positive control (AML
cell line U937) and negative control (multiple myeloma (MM) cell line U266), all four BALL cell lines show lack of endogenous (Figure 1B) NE and (Figure 2B) P3 mRNA
expression levels. Next, protein expression levels were analyzed. Positive and negative
controls for protein expression included AML cell like U937 along with soluble NE/P3
and breast cancer cell line MDA-MB-231, respectively. In comparison with positive and
negative controls, there also is a lack of endogenous NE (Figure 1C) and P3 (Figure
2C) protein expression in all four cell lines. Lastly, intracellular expression was
analyzed via flow cytometry. Cells were stained with live/dead aqua, fixed in 1%
formaldehyde, permeabilized in 5% perm solution and stained for intracellular
expression with anti-NE-Alexa Fluor (AF) 647 and anti-P3-AF488. Positive and
26
	
  
	
  

negative controls for intracellular expression were AML cell line U937 and breast
cancer cell line T47D, respectively. In comparison, a lack of endogenous intracellular
expression of NE (Figure 1D) and P3 (Figure 2D) was evident as well. Based on all four
methods, it was confirmed that all four lymphoblastic leukemia cell lines lack
endogenous expression of NE and P3. Therefore, any intracellular expression seen in
the presence of the aforementioned proteases was attributed to NE and P3 uptake.

3.1.2 B-ALL cell lines take up soluble and PMN-associated NE and
P3
Because we have previously shown that NE and P3 uptake occurred in APCs,
including B cells7, and the high expression of NE and P3 in the bone marrow, we
hypothesized the ALL cells take up NE and P3. B-ALL cell lines SB, Nalm6, RS4 and
SupB15 were co-cultured with 10 µg soluble NE and P3 at 10 minutes (Figure 3A-B)
and overnight time points (Figure 3C-D) and analyzed for intracellular uptake using flow
cytometry. Data indicated that uptake occurred in all four cell lines at both time points,
although at varying extents. Data shown displays the mean fluorescence intensity (MFI)
of pulsed versus non-pulsed ALL cells (Figure 3). The MFI following NE uptake at ten
minutes ranged from 210 to 587 (Figure 3A). Similar results were seen in P3 with a
range of uptake varying from MFI 464 to 1854 (Figure 3B). Overnight uptake was
similarly calculated for both NE and P3. The extent of NE uptake ranged from MFI 340
to 6166 (Figure 3C). A similar pattern was seen for soluble P3 at the overnight time
point with MFI ranging from 1629 to 7704 (Figure 3D). We further identified a timedependent increase in both NE and P3 uptake in SupB15, Nalm6, SB, and RS4 B-ALL
cell lines between the 10-minute and overnight time points (Figure 3).
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Figure 1: B-ALL cell lines lack endogenous expression of NE. U937 and HL70 were
used as positive controls. 231; MCF7, Jurkat, T47D, U266, and 453 cells were used as
negative controls. (A) mRNA expression levels were first determined using the Cancer Cell
Line Encyclopedia (CCLE). (B) mRNA was extracted from B-ALL cell lines. RT-PCR was
performed using NE primers and shows a lack of mRNA expression levels. (C) Western
blots demonstrate a lack of NE protein expression. AML cell line U937 was used as a
positive control for protein expression and actin was used as a loading control. (D) Flow
cytometry shows absence of intracellular NE expression compared to U937, positive control,
and T47D, the negative control.
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Figure 2: B-ALL cell lines lack endogenous expression of P3. U937 and HL70 were
used as positive controls. 231; MCF7, Jurkat, T47D, U266, and 453 cells were used as
negative controls. (A) mRNA expression levels were first determined from publically
available from the Cancer Cell Line Encyclopedia (CCLE). (B) mRNA was extracted from
B-ALL cell lines. RT-PCR was performed using P3 primers and shows a lack of mRNA
expression levels. (C) Western blot demonstrates a lack of NE protein expression. Purified
P3 (10 ug) was used as a positive control. Actin was used as a loading control. (D) Flow
cytometry shows absence of intracellular NE expression compared to U937 and T47D,
positive and negative controls, respectively.
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Figure 3: B-ALL cell lines take up soluble NE and P3. (A) Nalm6, RS4, SupB15
and SB cell lines were incubated with soluble NE (10 µg/mL) for 10 minutes (A) and
24 hours (C). Similarly all four cell lines were incubated with soluble P3 (10 µg/mL)
for 10 minutes (B) and 24 hours (D). Samples were then intracellularly stained with
anti-NE-AF647 or anti-P3-AF488 and analyzed by flow cytometry for intracellular
uptake. Data are means +/- SEM and represent three independent experiments. MFI
is plotted on the y-axis.
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To confirm that the positive fluorescence via flow cytometry reflected intracellular
NE and P3 that resulted from uptake, we co-cultured all four B-ALL cell lines with
soluble NE and P3 and acquired real-time images using the ImageStream X Mark II.
Cells were co-cultured with soluble NE and P3 (10 µg/mL) overnight, fixed in 1%
formaldehyde, permeabilized with 5% perm solution and stained with anti-NE-AF647,
anti-P3-AF488, and Hoechst-33342. Data indicated that all B-ALL cell lines take up NE
and P3 when co-cultured with soluble proteases indicated by intracellular positive
fluorescence (Figure 4).
In further studying the kinetics of NE and P3 uptake, we wanted to determine the
degree of uptake over time. SB, Nalm6, RS4 and SupB15 cell lines were co-cultured
with soluble NE and P3 (10 µg/mL) for 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours.
After each incubation period, cells were stained with Live/Dead Aqua, fixed in 1%
formaldehyde, permeabilized in 5% perm solution, and intracellular stained with antiNE-AF647 and anti-P3-AF488. Data confirmed earlier results describing the variance in
the degree of uptake between each cell line (Figure 5). Further, after 1 hour of coculture, uptake of both NE and P3 plateaus over time, suggesting a receptor-mediated
process for both NE and P3 uptake (Figure 5).
Different cellular pathways are involved in the uptake and processing of soluble
versus cell-associated proteins. This can then determine whether or not they are crosspresented. We therefore evaluated whether there was a difference between the uptake
of soluble and cell-associated NE and P3 in B-ALL cell lines. Each cell line was cocultured at 3 hours and 24 hours with soluble NE and P3 (10 µg/mL), irradiated PMNs
(7500 cGy) and resting PMNs at a ratio of 3:1 (PMN:B-ALL). PMN and PBMCs

	
  

31

	
  

DAPI

NE

P3

RS4

SB

Nalm6

SupB15

Figure 4: Intracellular uptake of NE and P3 occurs in RS4, SB, Nalm6 and SupB15
B-ALL cell lines. To confirm that NE and P3 expression indicated by flow cytometry was
indicative of intracellular uptake, B-ALL cell lines were co-cultured with soluble NE and
P3 (10 µg/mL) overnight. After co-culture, cells were fixed in 1% formaldehyde,
permeabilized in 5% perm solution, and intracellularly stained with anti-NE-AF647, antiP3-AF488, and DAPI. Samples were analyzed on the ImageStreamX Mark II.. Channel 7
indicates DAPI expression; channel 9 of side scatter, channel 11 indicative of NE
expression and channel 2 on P3 expression.
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Figure 5: Uptake of soluble NE and P3 plateaus over time in
B-ALL cell lines. SB, Supb15, RS4 and Nalm6 B-ALL cell lines
were co-cultured with soluble NE and P3 (10 µg/mL) at
increasing time points, and analyzed for uptake of (A) NE and
(B) P3. Fold increase of the MFI of NE or P3 versus unpulsed
cells is shown on the y-axis. Data indicated that after 1 hour of
co-culture, both NE and P3 uptake plateaus indicative of
receptor-mediated uptake.
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intracellularly stained for NE and P3 were used as positive and negative staining
controls, respectively. Data indicated that all four B-ALL cell lines took up both soluble
and PMN-associated NE (Figure 6) and P3 (Figure 7). In fact, uptake from the PMN
source was more efficient compared with uptake from soluble NE and P3 (Figure 6-7).
This may be due to the association of NE and P3 with other neutrophilic proteins that
could play a role in assisting in uptake of NE and P3. Similarly to soluble NE and P3,
the degree of uptake of PMN-associated proteases varied among cell lines. SupB15
and RS4 took up PMN-associated NE and P3 (Figure 6/7C-D) at the greatest extent,
and although Nalm6 and SB cell lines also took up P3, it was at a significantly lesser
extent than that of soluble (Figure 6/7A-C). Tables 2 and 3 display the fold increase in
MFI versus unpulsed cells of PMN-associated and soluble uptake. This data is
representative of data showing uptake of PMN-associated versus soluble (Figure 6-7).
Together our results showed that B-ALL cell lines lack endogenous NE and P3
but can internalize NE and P3 from exogenous sources.

3.1.3 P3 is taken up at a greater extent than NE in B-ALL cell lines
To further characterize NE and P3 uptake, we next sought to compare the
efficiency of NE versus P3 uptake. We co-cultured B-ALL cell lines, SB, Nalm6,
SupB15 and RS4, with soluble NE and P3 (10 µg/mL) and resting healthy PMNs at a
ratio of 3:1 (PMN: B-ALL) overnight, and compared the extent of intracellular uptake.
Our data showed significantly greater uptake of PMN-associated and soluble P3
compared with PMN-associated and soluble NE in the SB, Nalm6 and RS4 cell lines
(Figure 8A-C). This result was consistent with prior data from our lab showing that P3
uptake was greater than NE uptake 6. However, in SupB15 cell line, there was no
significant difference between the uptake of cell-associated and soluble NE and P3
	
  

34

	
  

**

1500

*
1000

*

500

Soluble NE

**

1000

***

0

Time Points

D
SupB15
15000Nonpulsed

3 hour

Time Points

Nonpulsed

1000

24 hour

500

3 hour

Anti NE-647 MFI

	
  

F
Irr PBMC pulsed

1500

0

200
150
100
50
0

Soluble NE pulsed

*

*

Time Points

Negative control for uptake
2000

Whole PMN pulsed

**
Sol NE pulsed

5000

Anti NE-647 MFI

E

Nonpulsed

10000

3 hour

ns

Anti NE-647 MFI

*

0

****

ns

Whole PMN pulsed

24 hour

Anti NE-647 MFI

****

4000

2000

****

****

6000

****

**

500

50000
45000
40000
35000
30000
25000
5000
4000
3000
2000
1000
0

Staining controls

PBMC

RS4

***

Soluble NE

***

Time Points

C

Nonpulsed

Soluble
WholeNE
PMN

PMN

3 hour

0

1500

Whole PMN

**

Nonpulsed

2000 Whole PMN

Nonpulsed

24 hour

2000

2500

***

*

SB

24 hour

	
  

*

24 hour

Anti NE-647 MFI

2500

B

3 hour

	
  

***

Nalm6

Anti NE-647 MFI

A

Figure 6: PMN-associated NE is taken up in B-ALL cell lines. Nalm6 (A), SB (B),
RS4(C) and SupB15(D) cell lines were co-cultured with resting PMNs at a ratio of 3:1
(PMN: B-ALL) and soluble NE (10 µg/mL) for 3 hours and 24 hours. Samples were
then surface stained for common B-ALL cell markers (CD19, CD34, CD38, CD10) as
previously mentioned, fixed in 1% formaldehyde, permeabilized in 5% perm solution,
intracellularly stained with anti-NE-AF647 Ab, and analyzed via flow cytometry. (E) BALL cell lines were pulsed with PBMCs as a negative control for uptake. (F) PMNs and
PBMCs were stained for intracellular NE and P3 as a positive and negative staining
control, respectively. Unpulsed cells (black bar) demonstrate baseline staining for NE
and P3, as they do not endogenously express either protein (Figure 1/2). Results are
representative of two independent experiments. Data indicated that PMN-associated
NE is taken up in all B-ALL cell lines at varying extents. Uptake of PMN-associated is
also at a greater extent than soluble NE.
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Table 2: Uptake of PMN-associated versus soluble NE in B-ALL cell lines
	
  

Cell Line
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PMN Source (Fold
Change vs. Unpulsed)

Soluble NE (Fold
Change vs. Unpulsed)
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Figure 7: PMN-associated P3 is taken up in B-ALL cell lines. Nalm6 (A), SB (B),
RS4 (C) and SupB15 (D) cell lines were co-cultured with PMNs at a ratio of 3:1 (PMN:
B-ALL) and soluble NE for 3 hours and 24 hours. Samples were then surface stained
for common B-ALL cell markers (CD19, CD34, CD38, CD10), fixed in 1%
formaldehyde, permeabilized in 5% perm solution, intracellularly stained with anti-NEAF647 Ab, and analyzed via flow cytometry. (E) B-ALL cell lines were pulsed with
PBMCs as a negative control for uptake. (F) PMNs and PBMCs were stained for
intracellular NE and P3 as a positive and negative staining control, respectively.
Unpulsed cells (black bar) demonstrate baseline staining for NE and P3, as they do not
endogenously express either protein. Results are representative of two independent
experiments.
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Table 3: Uptake of PMN versus soluble P3 in B-ALL cell lines
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Figure 8: Soluble and PMN-associated P3 is taken up at a greater extent
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than soluble and PMN-associated NE in Nalm6, RS4 and SB cell lines. BALL cell lines were co-cultured with PMN at a ratio of 3:1 (PMN: B-ALL) and
10
soluble NE and P3 overnight. After incubation period, cells were surface stained
for B-ALL markers, as previously described, fixed in 1% formaldehyde,
0
permeabilized in 5% perm solution and intracellularly stained with anti-P3AF488 and anti-NE-AF647. Data indicated that PMN-associated and soluble P3
is taken up at a greater extent than NE in RS4, Nalm6 and SB cell lines. In
SupB15 cell line, there was no significant difference in uptake between PMNassociated and soluble NE and P3. Data are means +/- SEM and represent
three independent experiments.
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(Figure 8D). Data further confirmed the variance in the degree of uptake of both NE
and P3 among all four cell lines.

3.1.4 Endogenous HLA-A2 surface expression in B-ALL cell lines
Due to the fact that PR1 is an HLA-A2 restricted peptide, endogenous surface
expression of HLA-A2 in SB, Nalm6, SupB15 and RS4 B-ALL cell lines was
determined. Two of the four cell lines, SB and Nalm6, were positive for endogenous
HLA-A2 surface expression (Fig. 9A-B) compared to that of both nonstained and
isotype control staining. Because SupB15 and RS4 cell lines did not endogenously
express surface HLA-A2 (Figure 9C-D), they were transduced with a HLA-A2 lentivirus
as previously described 46 in order to further investigate the phenomenon of PR1 crosspresentation. The SupB15 cell line was successfully transduced, as indicated by the
increase in MFI compared to nonstained, isotype control, and non-transduced group
(Figure 9C). The SB cell line had the highest surface HLA-A2 expression indicated by
the highest MFI (MFI = 16,368) compared to that of SupB15 (MFI = 4024) and Nalm6
(MFI = 2368) (Figure 9A-C). These three cell lines were used in all cross-presentation
experiments in the subsequent studies.

3.1.5 NE and P3 are cross-presented by B-ALL cell lines
Data up to this point indicated that all four cell lines took up both soluble and
PMN-associated NE and P3. Because PR1 is derived from NE and P3, we investigated
whether HLA-A2+ B-ALL cell lines cross-present PR1. HLA-A2-positive cell lines, SB,
Nalm6 and SupB15, were co-cultured with 10 µg/mL soluble NE/P3 and irradiated
PMNs (7500 cGy) for 24 hours to determine whether protease uptake resulted in PR1
cross	
  

40

	
  

D

Isotype

HLA-A2

RS4

820
815
810
805
800
800
600
400
200
0

RS4

Isotype

Transduced

Non-Transduced

Isotype

Anti HLA-A2-FITC MFI

SupB15

Nonstained

Nonstained

HLA-A2

4000
3500
3000
2500
2000
800
600
400
200
0

Nalm6

Nonstained

C
Anti HLA-A2-FITC MFI

Isotype

Anti HLA-A2-FITC MFI

20000
18000
16000
14000
12000
10000
800
600
400
200
0

5000
4500
4000
3500
3000
2500
800
600
400
200
0

B

SB

Nonstained

Anti HLA-A2-FITC MFI

A

Figure 9: Nalm6 and SB B-ALL cell lines are endogenously HLA-A2 positive. B-ALL
cell lines were stained for surface HLA-A2 expression with anti-HLA-A2 (BB7.2)-FITC
and analyzed by flow cytometry. MFI was compared to that of isotype control staining
and unstained samples. Data indicated that cell lines Nalm6 and SB cell lines were
positive for endogenous HLA-A2 surface expression and SupB15 and RS4 negative.
After transduction with a lentivirus, SupB15 cell line was positive for surface HLA-A2
expression compared to isotype control, unstained and non-transduced group.
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presentation. Cells were analyzed for PR1/HLA-A2 surface expression using the
mouse anti-PR1/HLA-A2 antibody 8F4, as previously described6,43. Data showed that
the B-ALL cell line, SB, cross-presents PR1 from soluble NE, soluble P3 and PMNassociated proteases (Figure 10A) compared to nonpulsed cells. Cell lines Nalm6 and
SupB15 did not cross-present PR1as indicated by a lack of significant uptake following
co-culture with NE and P3 (Figure10B-C).

3.1.6 PR1 cross-presentation renders B-ALL cell line susceptible to
PR1-CTLs
Because PR1 has been effectively targeted in myeloid leukemia using PR1targeting immunotherapies including PR1 vaccine25, PR1-CTLs2 and anti-PR1/HLA-A2
Ab, 8F44,5, we then investigated whether PR1 cross-presentation by B-ALL, more
specifically the SB cell line, rendered it susceptible to killing by PR1-CTLs. Based on
previous data showing that the HLA-A2 positive cell line, SB, cross-presents PR1 (Fig
10A), SB cell line was co-cultured with 10 µg/mL soluble NE and P3 for 24 hours and
incubated with healthy PR1-CTLs for 4 hours following a protocol for a standard
calcein-AM cytotoxicity assay 15,49. T2 cells were pulsed with PR1 and CG1 peptide as
a positive and negative control, respectively. Data indicated that when co-cultured with
PR1-CTLs, there was a dose-dependent killing of SB cells following PR1 crosspresentation compared to nonpulsed cells (Figure 10E). The percent specific lysis
when co-cultured with soluble NE and P3 reached a maximum of 30% at higher doses
and killing began at a very early ratio of 0.625:1 (Effector: Target) (Figure 10E). T2 cells
pulsed with PR1 also had dose-dependent killing by PR1-CTLs, whereas T2 cells
pulsed with CG1 and nonpulsed did not get killed, as expected (Figure 10D). ,
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Overall, data indicated that B-ALL cell lines are capable of soluble and PMNassociated NE and P3 uptake, and PR1 cross-presentation rendering B-ALL
susceptible to killing by PR1-CTLs. 	
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Figure 10: Cross-presentation of soluble NE and P3 increases B-ALL susceptibility to
killing by PR1-CTLs. HLA-A2+ B-ALL cell lines (A) SB, (B) Nalm6 and (C) SupB15 were
co-cultured with soluble NE and P3 (10 µg/mL), and irradiated PMNs (7500 cGy) overnight.
Cells were analyzed for surface expression of PR1/HLA-A2 with mouse anti-PR1/HLA-A2
Ab, 8F4. Data indicated that of 3 HLA-A2+ cell lines, only SB cell line cross-presents PR1.
MFI of PR1/HLA-A2 is shown on the y-axis. 2-way ANOVA was performed using Prism 5.0
software (****p = 0.0001, *p<0.05). Significance is comparing nonpulsed versus pulsed
cells. Data is representative of two independent experiments. (B) SB cells were cultured
overnight in serum free media (0.5%) containing soluble NE and P3 (10 µg/mL) loaded with
calcein-AM and then co-cultured with PR1-CTLs for 4 hours. Release of calcein-AM is
indicative of cell lysis. NE and P3 pulsed cells showed increased killing versus nonpulsed
SB cells. T2 cells pulsed with PR1 and CG1 or HIV peptide was used as a positive and
negative control in both experiments, respectively. Cytotoxicity data are means +/- SEM
from triplicate wells from 1 representative experiment.
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3.2 NETs serve as a possible source of NE and P3 uptake in B-ALL
cell lines
3.2.1 Identification of NET-inducing PMNs via flow cytometry
Gavillet et al. described a flow cytometry assay to identify and quantify NETs
through the identification of two essential and key indicators of NETosis: histone 3
citrullination (H3Cit) and MPO. H3Cit describes the conversion of arginine to citrulline
on histone tails and promotes chromatin decondensation, a key process in early
NETosis. After histone decondensation, NE and MPO drive nuclear membrane rupture
after recruitment to the nucleus. The latter marker is used in identifying PMNs
undergoing NETosis. This is a protocol that is observer-independent and allows
quantification of PMNs that will undergo NETosis. The gating strategy used included (i)
identifying DAPI+ cells, (ii) H3Cit+ cells and (iii) MPO+ cells. Therefore, triple positive
cells were considered PMNs undergoing NETosis48.
PMNs isolated from a healthy buffy coat were treated with both PMA (100 nM)
and Ionomycin (4 µM) as previously described 48, and incubated for four hours at 37 °C
with 5% CO2 in air. After incubation, cells were fixed in 2% formaldehyde, blocked and
incubated with primary anti-histone H3Cit Ab, AF647-conjugated secondary Ab, and
anti-MPO-FITC Ab, sequentially. After staining, cells were resuspended in Hoechst
33342, trihydrochloride trihydrate and analyzed via flow cytometry. Data showed that
both PMA and ionomycin induce NET formation as indicated by the shift in H3Cit and
MPO expression compared to nontreated PMNs (Figure 11). However, treatment with
ionomycin induced a greater population of NETosing PMNs indicated by a higher H3
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Cit+ population (Figure 11). Therefore, ionomycin was used for inducing NETosis in the
subsequent studies.

3.2.2 Identification of NET-inducing PMNs via confocal microscopy
In order to confirm that triple positive cells identified by flow cytometry were
indeed NETosing PMNs, NETosing PMNs were stained with other NETosis markers,
including DNA, NE, MPO, and P3, and identified via confocal microscopy. PMNs
isolated from a healthy buffy coat were treated with ionomycin (4 µM) and incubated for
four hours at 37 °C and 5% CO2. Cells were then fixed, and stained with Hoechst, antiNE-AF647, anti-P3-AF488, and anti-MPO-AF488. Results indicated that healthy PMNs
treated with Ionomycin undergo NETosis. This is evident by the presence of DNA
extruded from the cell and extracellular expression of NE and MPO (Figure 12B).
Confocal microscopy also confirmed that nontreated PMNs do not spontaneously
undergo NETosis (Figure 12A). NE was proven very abundant in the NET structure,
agreeing with published data (Figure 12B). However, P3 expression was not abundant
in the NET structure but was instead intracellular (Figure 12C).

3.2.3 NET-associated NE and P3 are taken up by B-ALL cell lines
NETosis induces the release of neutrophil cytoplasmic granules, such as NE
and P3, into the tumor microenvironment. To evaluate whether NET-associated NE and
P3 are a source of uptake in B-ALL, healthy PMNs were treated with ionomycin (4 µM)
and co-cultured with B-ALL cell lines overnight. After incubation, B-ALL cell lines were
stained for surface markers, as described in an earlier section, live/dead Aqua and
intracellular NE and P3 uptake with anti-NE-647 and anti-P3-AF488. Notably, in
overnight co-culture, such interaction
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Figure 11: PMA and ionomycin induce NET formation in healthy PMNs,
ionomycin at a greater extent. PMNs were isolated from a healthy donor and treated
with PMA (100 nM) and ionomycin (4 µM) for four hours at 37 °C to induce NET
formation. Cells were then stained with identifying markers for early NETosis: H3
citrullination and MPO, fixed in 1% formaldehyde and stained with DAPI. Cells triple
positive for DAPI, H3Cit and MPO were considered NETosing PMNs. NETs were
detected in both forms of treatment. Ionomycin induced a higher population of NETs
indicated by the higher percentage of H3Cit+MPO+ population.
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Figure 12: PMNs treated with ionomycin undergo NETosis. (A) Untreated PMNs
were stained with anti-NE-AF647 (red), anti-MPO-AF488 (green) and Hoechst
(blue/purple), and then imaged using confocal laser microscopy. Untreated PMNs do
not appear to undergo NETosis without stimulation. Hoechst was used to stain nuclei.
(B) Healthy PMNs from the same donor were stimulated with ionomycin (4 µM) for four
hours at 37 °C to induce NET formation. Samples were seeded on a cover slip, fixed in
1% formaldehyde, blocked and stained with anti-NE-AF647 (red), anti-MPO-AF488
(green), and Hoechst (blue/purple) and then imaged using confocal laser microscopy.
Images indicate that PMNs stimulated with ionomycin extrude DNA and an abundance
of NE (pink/purple), indicative of NETosis. (C) Samples were treated in a similar
manner and stained with anti-NE-AF647 (red), anti-P3-AF488 (green) and Hoechst
(purple) and then imaged using confocal microscopy. Similar to (B), when stimulated,
healthy PMNs will extrude DNA and an abundance of NE (red/purple) indicative of
NETosis. However, the abundance of P3 in the NET’s contents is not as high as that of
NE. This data agrees with published work on the abundance of granules located in
NET contents.
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resulted in both NE (Figure 13) and P3 (Figure 14) uptake in all four B-ALL cell lines.
Flow cytometry showed that although both NET-associated and PMN-associated NE
and P3 are both taken up, uptake in resting PMNs was significantly greater (Figure 67). Similar to uptake of soluble and PMN-associated proteases, uptake between cell
lines varied greatly. Co-culturing with resting PMNs was used as a positive control as
we have previously shown this to be a source of protease uptake (Figure 6-7).
Sangaletti et al proved that the integrity of the DNA backbone in the structure of
NETs is necessary in maintaining the structural and functional integrity of its contents.
Therefore, NETs were treated with DNAse to determine the effect on uptake once
granules were released from the DNA backbone. Data indicated that denaturing of the
NET structure inhibited NE uptake in B-ALL cell lines (Figure 13-14), agreeing with the
aforementioned study. Further, treatment with DNAse showed a dose-dependent
decrease in NE uptake, but did not affect P3 uptake (Figure 15). This would be
expected, as NE is of much greater abundance than P3 in the NET structure.
To further prove that uptake of NET-associated NE and P3 occurred, we wanted
to determine whether the treatment of ionomycin or DNAse itself had any significant
effect on uptake. To test this, we co-cultured all four B-ALL cell lines with irradiated
PMNs (7500 cGy), and resting PMNs at a ratio of 3:1 (PMN: B-ALL), along with soluble
NE and P3 (10 µg/mL). Each treatment group was also treated with ionomycin (4 µM)
or DNAse (100 U/mL) to determine if there was any effect on NE (Figure 16) and P3
(Figure 17) uptake. Data indicated that neither treatment group had any effect on
uptake at any of the four conditions (Figure 16-17). Therefore, data further proved that
NETs serve as a source of NE and P3 uptake, however at a lesser extent than resting
PMNs.

	
  

49

	
  

In a previous section, we identified the uptake PMN-associated NE and P3 in BALL cell lines. However, to be able to properly differentiate between PMN-associated
and NET-associated, it was important to determine whether resting PMNs and
irradiated PMNs undergo NETosis spontaneously. To test this, we isolated PMNs from
a healthy donor and stained for important early NETosis markers, H3Cit and MPO, as
described in an earlier section. Cells were also stained with Hoechst, a DNA dye. Data
showed that neither resting nor irradiated PMNs underwent NETosis as indicated by
the negative expression of H3Cit and MPO (Figure 18).
Overall, data indicated that ionomycin and PMA induce healthy PMNs to
undergo NETosis, a process that initiates NE and P3 uptake in B-ALL cell lines. It was
also shown that the integrity of the NET backbone is necessary in maintaining NE
uptake.
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Figure 13: NET-associated NE is taken up in B-ALL cell lines. (A) RS4, (B) Nalm6, (C)
SB and (D) SupB15 cell lines were co-cultured with resting PMNs, PMNs treated with
ionomycin (NETs) and NETs treated with DNAse overnight. After this time point, samples
were surface stained with common B-ALL markers (CD10, CD19, CD34 and CD38) and
live/dead Aqua, fixed in 1% formaldehyde, permeabilized in 1% solution, and stained for
intracellular uptake with anti-NE-AF647. Data indicated that NET-associated NE is taken up
in all four B-ALL cell lines, but at a significant lesser extent than resting PMNs. Further,
treatment with DNAse inhibited uptake in SupB15, Nalm6 and RS4 cell lines. PMN and
PBMC stained for intracellular expression of NE and P3 were used as a positive and
negative control, respectively. MFI is on the y-axis, and the axis is in log scale. A two-way
ANOVA was performed using Prism 7.0 software (*p<0.005)
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Figure 14: NET-associated P3 is taken up in B-ALL cell lines. (A) RS4, (B)
Nalm6, (C) SB and (D) SupB15 cell lines were co-cultured with resting PMNs,
PMNs treated with ionomycin (NETs) and NETs treated with DNAse overnight.
After this time point, samples were surface stained with common B-ALL markers
(CD10, CD19, CD34 and CD38) and live/dead Aqua, fixed in 1% formaldehyde,
permeabilized in 1% solution, and stained for intracellular uptake with anti-P3AF488. Data indicated that NET-associated NE is taken up in all four B-ALL cell
lines, but at a lesser extent than resting PMNs. Further, treatment with DNAse
had little effect on P3 uptake. PMN and PBMC stained for intracellular expression
of NE and P3 were used a positive and negative control, respectively. MFI is
expressed on the y-axis and is log scale. A two-way ANOVA was performed using
Prism 7.0 software (*p<0.005).
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Figure 15: DNAse treatment inhibits NE uptake in B-ALL cell lines in a dosedependent manner. PMNs were isolated from a healthy donor and treated with
ionomycin (4 µM) for four hours at 37 °C to induce NETosis. After incubation period,
PMNs were treated at increasing doses of DNAse (0,100,200,300,400 U/mL) for 1 hour
at 37 °C, and then co-cultured with B-ALL cell line overnight. At this time point, cells
were stained with B-ALL phenotypic markers (CD19, CD10, CD34, CD38) and
live/dead aqua, fixed in 1% formaldehyde, permeabilized in 5% perm solution, and
intracellularly stained with anti-NE-AF647 and anti-P3-AF488. Data indicates that
there is a dose-dependent decrease in uptake of NE (A) but no effect on P3 uptake
(B). MFI is on the y-axis.
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Figure 16: DNAse nor ionomycin have any effect on PMN-associated NE
uptake in B-ALL cell lines. (A) RS4, (B) Nalm6, (C) SB, and (D) SupB15 cell lines
were co-cultured with resting PMNs, irradiated PMNs (7500 cGy), and soluble NE
(10 µg/mL). Each condition was also treated with ionomycin (4 µM) and DNAse
(100 U/mL) and incubated overnight. After this time point, cells were stained for
common B-ALL phenotypic markers, as previously described, fixed in 1%
formaldehyde, permeabilized in 5% perm solution and stained for intracellular
uptake with anti-NE-647 Ab. MFI is displayed on the y-axis and the axis is shown in
log scale. Data indicated that neither ionomycin nor DNAse treatment had any
significant affect on PMN-associated NE uptake. Cells were analyzed by flow
cytometry for intracellular uptake of NE. PMN and PBMC were used as positive and
negative staining controls, respectively. A two-way ANOVA was performed using
Prism 7.0 software (*p<0.005).
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Figure 17: DNAse nor ionomycin have any effect on PMN-associated
P3 uptake in B-ALL cell lines. (A) RS4, (B) Nalm6, (C) SB, and (D)
SupB15 cell lines were co-cultured with resting PMNs, irradiated PMNs
(7500 cGy), and soluble NE (10 µg/mL). Each condition was also treated
with ionomycin (4 µM) and DNAse (100 U/mL) and incubated overnight.
Similar staining protocol was performed to data showing effect on NE
uptake (Figure 16). MFI is displayed on the y-axis and the axis is in log
scale. Data indicated that neither ionomycin nor DNAse treatment had any
significant affect on PMN-associated NE uptake. Cells were analyzed by
flow cytometry for intracellular uptake of NE. PMN and PBMC were used
as positive and negative staining controls, respectively. A two-way ANOVA
was performed using Prism 7.0 software (*p<0.005).
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Figure 18: Resting and Irradiated PMNs do not undergo NETosis without
stimulation. Resting and irradiated (7500 cGy) PMNs were stained for markers of
early NETosis, H3Cit and MPO, as previously describe in an earlier section. Cells
were then fixed in 1% formaldehyde, stained with Hoechst, and analyzed via flow
cytometry. Gating strategy was one described earlier in identifying PMNs
undergoing NETosis. Triple positive cells (Hoechst+H3Cit+MPO+) are indicative of
NETosing PMNs. Data indicated that neither resting nor irradiated PMNs were
positive for H3Cit or extracellular MPO. Therefore, PMNs without stimulation do not
undergo spontaneous NETosis.
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Chapter Four: Discussion and Future Direction
4.1 Discussion
NE and P3 are serine proteases stored in cytoplasmic azurophilic granules, and
are expressed in myeloid derived cells such as granulocytes, monocytes, mast cells,
and bone marrow myeloid progenitors. Both play large roles in granulocyte
development in the bone marrow50-52, and in antimicrobial defense through engulfment
and degradation of foreign antigen 13,53. NE and P3 are found in tumors with
neutrophilic and monocytic infiltration. PR1, an antigen derived from NE and P3, is
overexpressed in myeloid leukemia and has been successfully targeted by PR1targeting immunotherapies including PR1-CTLs 17,24, PR1 peptide vaccine 25, and antiPR1/HLA-A2 (8F4) mAb 4,5.
The major aim of this thesis was to validate PR1 as an immunotherapeutic target
in B-ALL. This was hypothesized based on data showing that APCs, including B-cells,
cross-present PR1 7. To further strengthen this hypothesis, B-ALL is located in the
bone marrow, which is abundant in PMNs, and therefore NE and P3. We show in this
study that B-ALL cell lines (SB, Nalm6, RS4 and SupB15), which lack endogenous NE
and P3, take up soluble and PMN-associated NE and P3 (Figures 3,6,7). More
importantly, we identify PR1 cross-presentation in the HLA-A2+ cell line, SB, rendering
it susceptible to killing by PR1-CTLs (Figure 10). This thesis provided further evidence
of a mechanism where myeloid derived antigens are taken up and cross-presented on
MHC class I by malignancies that do not endogenously express NE and P3. It also
further identified tumor types susceptible to killing by efficacious PR1 targeting
immunotherapies.
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The need to identify and develop forms of treatment that target specific antigens
expressed on malignant cells is further highlighted by the relationship between the GvL
effect and the toxicity and high rate of GvHD that occur after an allo-SCT. To date,
many targeted immunotherapies focus on T cells specific for neo-antigens. These
responses are typically to mutations in proteins that drive tumorigenesis54. However,
some tumor types, such as B-ALL, do not have many distinctive immunogenic
mutations to be targeted. Therefore, identifying tumor-associated antigens, even if
normal proteins, that are expressed at a higher rate on malignant cells is an important
first step in targeted therapy in B-ALL.
To date, there are few antigen-specific therapies in B-ALL. Our data, however,
identified PR1 as a target of interest in B-ALL. Current forms of treatment that can be
utilized in targeting PR1 in B-ALL include PR1 vaccine1,25, PR1-CTLs16 and 8F4
mAb4,5, all efficacious in inducing lysis of malignant cells. PR1-CTLs were shown to
contribute to remission in myeloid leukemia patients treated with interferon and
allogeneic stem cell transplant 17,24. The successful killing of chronic and acute myeloid
leukemia cells by PR1-CTLs supports the targeting of surface PR1 to elicit an immune
response and the boosting of anti-leukemia responses. PR1 vaccine induced and
enhanced leukemia-specific CD8+ T cell responses to PR1 in myeloid
malignancies1,22,25. The response of PR1 vaccine treatment was robust due to a higher
frequency of PR1-specific CD8+ T cells with a memory phenotype in leukemia patients
in comparison to healthy individuals 17,21,23. 8F4 mAb, engineered in our lab, was
proven successful in targeting chronic and acute myeloid leukemia4,5 and non-myeloid
malignancies including breast cancer, melanoma6,42 and lung cancer.43 It was shown
the 8F4 mediated CDC against LSCs and prevented growth of progenitor cells in
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myeloid leukemia4. With high affinity binding to the PR1/HLA-A2 complex, it was also
proven that 8F4 induced dose-dependent cytolysis in malignant cells but had no effect
on normal hematopoietic cells4.
Despite data from our lab proving the anti-leukemia activity of 8F4, there are
some caveats that exist in its use. For example, its inability to cross the blood brain
barrier5. This can be worrisome in some leukemia types that spread to the brain and
central nervous system. A second limitation is the expression of PR1/HLA-A2 complex
on the surface of healthy B cells after NE and P3 uptake7. PR1/HLA-A2 surface
expression on healthy B cells identified the possibility of lysis of healthy B cells with
8F4 treatment resulting in B-cell aplasia when treating B-ALL patients. Although lysis of
healthy B cells is not ideal, patients can be treated with antibiotics and infusional
gamma globulin until the B cell population is no longer depleted55. It is also important to
consider the advantages of treatment despite the possibility of targeting healthy B cells.
Although B-ALL patients have a high rate of response to initial therapy, 50% of patients
in remission will relapse. Relapsed disease is quite aggressive and the only form of
treatment in an allo-SCT, which has risks itself. Because relapse is hypothesized to be
due to the growth of leukemic stem cells that are resistant to induction chemotherapy,
treating with 8F4 that targets and lyses LSC is critical in enhancing the development of
curative treatment in B-cell ALL.
Data in this thesis identified cross-presentation as a critical mechanism in
generating an effective CTL response. Cross-presentation is a mechanism wherein
exogenous antigen, such as tumor-derived antigen, is endocytosed and bound to MHC
class I molecules. This process occurs in professional APCs including DCs, B cells,
macrophages and neutrophils 56-58, and plays an important role in eliciting immune
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responses against tumor antigens. Although DCs are considered the cell most likely to
cross-present due to high levels of MHC class I/II, and T cell costimulatory molecule
expression, literature has verified that B cells are capable of cross-presentation as well.
Heit et al showed when mice are immunized with CpG-DNA complexed with OVA, B
cells are activated and capable of cross-priming OVA-specific CD8+ T cells 59.
Following adoptive transfer of B cells that cross-present CpG-OVA, further in vivo work
identified the priming and differentiation of naïve CD8+ T cells to OVA-specific CTLs. A
second study identified the ability of B cells to internalize Salmonella after recognition
and internalization via B cell receptor (BCR). Salmonella antigens were crosspresented in a proteasome-dependent manner on MHC class I molecules reactivating
CD8+ memory T cells that expressed a cytotoxic phenotype, and were proven efficient
in killing Salmonella-infected cells60. Studies not only identified the ability of B cells to
cross-present viral antigens, but self-antigens as well. Marino et al showed that B cells
cross-present islet-derived autoantigens that are recognized by self-reactive CD8+ T
cells in the pancreatic lymph node61. The result is the expansion of CD8+ T cells into
effector cells. These studies agree with our findings identifying uptake and crosspresentation of antigens in B cells as a mechanism for inducing a robust CTL response
(Figure 10) in B-ALL.
Although all aforementioned cells are capable of cross-presentation, the
efficiency at which APCs take up antigen differs amongst each cell type 62. Heit et al
showed that B cells are not as efficient as DCs in antigen uptake, indicated by cellular
uptake occurring in only 50% of B cells59. This is also similar to other work done in our
lab identifying the variance in NE and P3 uptake not only between cell lines, but
between tumor types as well, including breast, pancreatic, melanoma, ovarian and

	
  

60

	
  

colon carcinomas 6,42. We speculate this to be due to differences in the mechanisms of
protein uptake. Data from our lab indicated a dose-dependent increase in P3 uptake in
breast cancer cell lines suggesting a non-receptor mediated uptake6. On the other
hand, studies by Houghton et al showed NE was taken up by clathrin-coated vesicles,
and work in our lab identified NE uptake as time and dose-dependent42. Both
suggested NE uptake was a receptor-mediated mechanism42. In this study, uptake of
NE and P3 plateaued after 1 hour in B-ALL cell lines (Figure 5), indicating a receptormediated mechanism of uptake. This suggests a difference in uptake mechanisms in
tumor types, and can give reason as to why uptake in B-ALL cell lines, RS4, SupB15,
SB and Nalm6, varies greatly as well (Figures 3,6-7).
Tumor cells have acquired many survival mechanisms to evade the immune
system. This occurs by creating an immunosuppressive environment through cell
signaling enhancement in tumor infiltrating cells 63, and the down-regulation of MHC
and co-stimulatory surface expression. T cells specific for tumor antigen require two
signals to initiate activation and expansion. The first includes the binding of the TCR to
the peptide: MHC complex on the cell surface. The second is the interaction between
costimulatory molecules, such as CD80 (B7-1) and CD86 (B7-2), on the surface of the
APC that bind to CD28 on antigen specific T cells. Co-stimulatory signals are
responsible for the cascade of signaling that occurs from the TCR64, including cytokine
secretion, T cell proliferation and effector function65,66. Both TCR/MHC:peptide binding
and costimulatory receptor binding are critical in eliciting an anti-tumor response. Dai et
al described a phenomenon where despite high surface MHC class I and II expression,
B cell-CLL was not susceptible to T cell recognition67. Data indicated this was due to a
down-regulation in co-stimulatory molecule CD86 (B7-2) on the surface of the APC 67,
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inhibiting a primary immune response. Lack of CD86 expression on leukemic cells
inhibits the activation of effector T cells, and instead results in T cell anergy or
tolerance68,69. Hematopoietic malignancies such as AML, MM and, more importantly,
ALL have very low or lack CD86 expression70-73. In our study, down regulation of CD86
lends to the possibility that PR1 cross-presentation may lead to B-ALL tolerance. In BALL patients, these down regulated markers can be targeted to restore effector function
of PR1-CTLs and their expansion. Some possible forms of treatment include IL-7,
interferon (IFN)-  γ, and IL-12 treatment. Studies have shown all three forms of
treatment increase CD80 and CD86 surface expression enabling T cell recognition and
function74,75. This was seen in monocytes and in AML cell lines. CD8 T cell crosspriming against tumor antigens was also induced by type I IFN treatment through the
stimulation of APCs14,76. IFN treatment was also shown to play a role in enhancing
uptake and cross-priming against soluble and cell-associated antigens. It boosts the
differentiation of APCs, in this case DCs, into cells with high capacity for antigen and
cross-presentation76. A second study showed that IFN-  γ elevated MHC expression and
improved APC function in ALL cells77. These forms of treatment activated both arms
necessary to stimulate an immune response against tumor antigen: the ability to
process and express peptide/MHC for T cell recognition and the expression of
costimulatory molecules. This is important in our study because despite the capability
of PR1 cross-presentation in B-ALL cells, without the expression of costimulatory
molecules, treatment would prove to be ineffective, and would instead induce T cell
anergy. Future work would include identifying the loss or down-regulation of
costimulatory molecules, CD80 and CD86. We would then identify the effects of IL-7,
IL-12 and IFN- γ treatment in eliciting an immune response against PR1.

	
  

62

	
  

Further surface molecules that can modulate T cell activation include CD28 and
cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression on the APC surface. CD28 and
CTLA-4 provide stimulatory and inhibitory effects on CTLs, respectively. CD28
facilitates a T cell response through cytokine expression by binding to its ligands, CD80
and CD86, on the surface of the APC 66,78-81. On the other hand, CTLA-4, an inhibitory
signal, is an important negative regulator of the duration and intensity of antigenspecific T cell responses82,83. This function is modulated by the competition that exists
between CTLA4 and CD28 in binding B7 ligands CD80 and CD86 on the APC surface.
The engagement of CTLA-4 and its ligand inhibits effector T-cell function. Tumor cells
often express inhibitory ligands to selectively block antitumor immunity. Current studies
identify the up regulation of CTLA4 on leukemic cells 84,85 as a mechanism inhibiting a
cytotoxic T cell response. However, the design of a CTLA-4 checkpoint inhibitor,
ipilimumab, proved efficacious in inhibiting CTLA-4 binding and augmenting an effector
T cell response. Responses were associated with the expansion of cytotoxic CD8+ T
cells, decreased activation of regulatory T cells (Tregs) and expansion of
subpopulations of effector T cells in the blood85. It would be plausible to conclude that
dual treatment with CTLA-4 blockade and 8F4 mAb, treatment that induced lysis in
chemotherapy resistant cells and LSCs, would be synergistic and would serve as an
efficacious treatment for B-ALL patients.
Another important interaction that inhibits T cell function is between programmed
death (PD)-1 and programmed death ligand (PD-L1). This interaction induces an
inhibitory signal and promotes T cell apoptosis, anergy and functional exhaustion 86,87.
T cell activation induces surface expression of PD-1, and with cytokines produced after
T cell activation such as IFN- γ and IL-4, expression of PDL-1 is also induced
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establishing a feedback loop in maintaining T cell function88. In B-ALL, there is aberrant
expression of PD-L1 on malignant cells89, in addition to the surface of tumor-infiltrating
macrophages and APCs in the tumor microenvironment90,91. PD-L1 up regulation,
similar to CTLA-4, is to hinder CTL cytotoxicity and results in T cell exhaustion.
Targeted inhibition in B-ALL patients through mAb treatments may significantly affect
the efficacy of T cell based immunotherapies, such as PR1-targeted therapies.
A final mechanism of immune evasion includes the down regulation of HLA class
I surface expression on malignant cells, a phenomenon mainly identified in solid
tumors. A recent study however identified the loss of surface HLA class I molecules on
leukemic cells, specifically in relapsed patients 92, identifying this as a mechanism by
which tumor cells can evade T cell surveillance. HLA molecules expressed on the cell
surface, in complex with antigen, are necessary in the recognition of tumor-specific
CTLs. Often, tumor-specific antigens are intracellular proteins processed within the
APC and bound to HLA class I molecules92. Therefore, the loss or down-regulation of
HLA class I molecules would inhibit any effect of T cell based immunotherapy. The
therapy presented in my thesis, for example, is PR1 specific. Its effectiveness depends
completely on the HLA-A2/PR1 complex on the B-ALL cell surface. Consequently, loss
or down regulation of HLA class I molecules by leukemic cells would result in a lack of
PR1 cross-presentation and the ability to elicit immune response against B-ALL cells.
Therefore, restoring surface expression is important in the efficacy of targeted therapy.
Our study identified that co-culture with NE and P3 had no effect on HLA-A2 surface
expression in any of the HLA-A2+ cell lines. However, only one of the three HLA-A2+
cell lines proved capable of cross-presentation based on PR1/HLA-A2 surface staining
with anti-8F4-AF647 Ab. A possible mechanism in the inability to cross-present PR1 is
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the down-regulation of HLA-A2 surface expression. SB, the cell line shown to crosspresent PR1, had the highest surface expression of HLA-A2 and Nalm6 and SupB15
were at a lesser extent (Figure 9) identifying this reduction in expression a possible
form of immune evasion.
As previously mentioned, cancer progression is maintained by the interaction
between malignant cells and immune cells in the tumor microenvironment. Neutrophils,
a white blood cell of the innate immune system, are an important cell in contributing to
cancer progression through mechanisms including angiogenesis, and metastasis 93.
One method of action in initiating metastasis is through the formation of NETs. NETosis
is a unique form of neutrophil cell death, independent of apoptosis and necrosis, where
chromatin and cytoplasmic granules are externalized following nuclear and cell
membrane rupture. NETs play a large role in fighting bacterial infections through
entrapment and degradation by NET contents, and in conditions such as
atherosclerosis, diabetes and SLE 22,94-96. Skrzeczynska-Moncznik et al. showed that
NETs modulate the link between the innate and adaptive immune response through the
binding and activation of DCs via TLR997. This NET-mediated activation is important in
the establishment of autoimmune diseases such as psoriasis, and SLE. Berger-Achituv
et al. identified that NET-associated tumor antigens are taken up and displayed on DCs
for activation98. Additionally, this group showed that NETs can prime T cells through
TCR signaling98. These data support the idea that NETs can function as a danger
associated molecular patter (DAMP) to up-regulate an inflammatory response and
ultimately enhance an adaptive immune response. As mentioned earlier, NETs have
the ability to transfer neutrophil cytoplasmic proteins, including P3, to mDCs resulting in
cross-presentation that triggers an adaptive immune response as indicated by ANCA
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production45. Therefore, we postulate that NET-associated P3 is more likely to function
as a DAMP and reverse tolerance due to TLR9 activation and the P3 crosspresentation on DCs. Soluble P3 is more likely to invoke tolerance because it does not
function as a DAMP since it is not associated with other proteins or DNA.
However, in recent years, formation of NETs has been identified in the tumor
microenvironment. Most literature identified NET formation as being tumorigenic
through inducing metastasis, relapse, and cancer-associated deep vein thrombosis.
Cools-Lartigue et al. showed that NET structures released during infection initiate
metastasis by promoting tumor cell presence in the circulation99. Further, studies
identified the correlation between NET formation and relapse in patients with metastatic
colorectal cancer and Ewing sarcoma98. However, my data hints to a possible antitumor characteristic of NET formation in the tumor microenvironment. NE and P3 are
two neutrophilic proteases abundant in NETs. NE is required for nuclear
decondensation to occur100, and is the most abundant non-histone protein within the
NET structure. The abundance of neutrophils in the bone marrow, the immunogenicity
of NETs, and the presence of NE led us to hypothesize that NETs serve as a possible
source of NE and P3 uptake in the bone marrow microenvironment. Our data
demonstrated that NETs initiate the transfer of NET-associated NE and P3 to malignant
cells (Figure 13-14). This could then potentially lead to PR1 cross-presentation, and
allow for the use of PR1-targeting immunotherapies. This mechanism identified an antitumor effect of NET formation that could potentially be harnessed.
In conclusion, our results identified NE and P3 cross-presentation in B-ALL cell
lines rendering them susceptible to killing by PR1-CTLs. We also identified PMNassociated NE and P3 as the most efficient source of uptake in B-ALL, but more
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importantly, the ability of NETs to serve as a source of NE and P3 uptake. Because
PMNs infiltrate various tumor microenvironments and sites of inflammation, and are the
source of NE and P3, our findings suggest the ability of PR1-targeting
immunotherapies to target lymphoid malignancies. Data also further described crosspresentation as a novel mechanism rendering tumors susceptible to therapies that
target antigens not endogenously expressed.
An overall schematic is shown below identifying the three main steps in PR1
targeting in B-ALL (Figure 19). The first includes soluble, NET-associated and cellassociated NE and P3. The second includes the processing, cross-presentation and
targeting of PR1. This results in step 3 which is tumor cell lysis.
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Figure 19: Proposed model of uptake and cross-presentation of NE and P3 renders BALL cell lines susceptible to killing by PR1-CTLs, PR1-vaccine and 8F4 mAb. This
schematic identifies the overall process of PR1 cross-presentation. The first step includes
the uptake of soluble, NET-associated or cell-associated NE and P3. This then leads to PR1
cross-presentation and targeting by PR1-CTLs, PR1 vaccine and 8F4 mAb. This targeting
then leads to step 3, which includes tumor cell lysis.
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4.2 Future Directions
	
  

The data presented in this thesis identified the ability of B-ALL cell lines to cross-

present PR1; a peptide derived from serine proteases NE and P3, rendering them
susceptible to killing by PR1-CTLs. Although data has shown uptake, the ability to
cross-present varies among the cell lines. It would be important to determine the
whether uptake is receptor mediated, and if so, what antigen presentation machinery
components are involved in PR1 cross-presentation in B-ALL. This would include
treatment with proteasome and ER/Golgi inhibitors, and type I IFNs on PR1 crosspresentation. Treatment would include brefeldin A, which inhibits ER to Golgi transport
and lactacystin, which is a proteasome inhibitor. Both are aspects of classical antigen
presentation. Identifying the mechanisms involved in uptake can differentiate between
cell lines that cross-present PR1 and those that do not. It would also be important to
identify the expression of costimulatory molecules, such as CD86, and inhibitory
receptors, including CTLA-4, on B-ALL cell lines and patient samples. As previously
mentioned, both can have an effect on eliciting a T cell response against tumor antigen.
As previously mentioned, our data has proven B-ALL susceptible to killing by
PR1-CTLs. We would also determine the susceptibility to 8F4 lysis in vitro. Further, if
PR1 cross-presentation occurs rendering B-ALL susceptible to killing by 8F4, it would
be necessary to determine the mechanism of action of human 8F4 against B-ALL. As
mentioned earlier, previous data indicated mouse 8F4 induced cell lysis by CDC4,5. To
achieve this aim, we would conduct an annexin V apoptosis assay, as previously
described101, in addition to determining if cell lysis is mediated by antibody dependent
cytotoxicity assay (ADCC).
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This would be initial work prior to identifying the effects of 8F4 on eliminating
human B-ALL in vivo. In vivo work would include B-ALL cell lines injected into NSG
mice via tail vein injections. Engraftment would be confirmed each week through blood
drawings and tested for common B-ALL markers by flow cytometry. Once engraftment
is confirmed, mice would be injected with 8F4 at increased doses based on conditions
previously determined using AML in vivo NSG mouse studies4. Control groups would
include nontreated and isotype control groups. The effect of 8F4 would be determined
by blood draws and phenotyping for common B-ALL markers using flow cytometry, as
previously mentioned.
Although these findings are interesting, more importantly we need to identify the
presence of PR1/HLA-A2 and PR1-CTLs in B-ALL patient samples. Because B-ALL is
located within the bone marrow, a site abundant in PMNs and NE and P3, and studies
identified B-cells capable of PR1 cross-presentation, we expect the presence of
PR1/HLA-A2 surface expression in malignant cells and more importantly the presence
of PR1-CTLs in the bone marrow. We also expect these results as we have shown BALL cell line, SB, susceptibility to killing by PR1-CTLs. If cross-presentation was not
seen in patients as we have shown in cell lines, this can be attributed to the
heterogeneity of ALL cells. Further, PR1 can still be targeted by another phenomenon
termed cross-dressing if PR1 cross-presentation was not evident. This is a mechanism
that involves the transfer of peptide/MHC-class I complex on the surface to APCs
without the need for processing. In this case, the transfer from neutrophils with
PR1/HLA-A2 surface expression to malignant cells. The mechanism speculated to be
involved is trogocytosis, a process that where cell-surface proteins are rapidly
transferred when tumor cells are in contact with necrotic cells.
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We also have yet to determine the activity of PR1 targeting therapies against
primary B-ALL versus healthy B cells. In identifying the ability of healthy B-cells to
cross-present PR1, we would also determine the difference in surface expression
between malignant and healthy B-cells. This can identify the effects of 8F4 mAb
treatment and whether it would induce lysis of healthy B cells. If PR1/HLA-A2 were
expressed on normal hematopoietic stem cell (HSC) and LSC and because 8F4
eliminates LSCs, it would also be important to determine the effects of 8F4 on normal
hematopoiesis. If an effect was seen in healthy B cells, we would need to identify
methods of action in treating patients if B cell depletion occurs following 8F4 treatment.
Our study also identified NETs as a novel source of NE and P3 uptake in B-ALL
cell lines. Future studies include first identifying the existence of NETs in the B-ALL
microenvironment. Because it has been shown that only a fraction of neutrophils are
capable of forming NETs, we will also need to identify whether neutrophils in the bone
marrow are capable of NETosis surrounded by malignant cells and their stimuli. It
would also be important to determine the balance between pro- and anti-tumor effects
of NETs produced in the B-ALL microenvironment. Because most studies on NETs in
the tumor microenvironment indicate pro-tumor effects including metastasis and
thrombosis, identifying the balance that exists between pro- and anti-tumor effects can
be important. If we would be able to harness the anti-tumor effects and up regulate
NETosis and NE and P3 uptake, then lysis of malignant cells by PR1-targeting
therapies can also be increased.
Because there are various mechanisms for transfer of tumor antigen to APCs for
cross-presentation, there may exist various forms in the B-ALL microenvironment that
lead to NE and P3 uptake. One possible example includes the secretion of exosomes
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from neutrophils in the bone marrow to be endocytosed by the malignant cell.
Exosomes released into the microenvironment have the ability to induce immune
response, cell migration, cell differentiation and various aspects of cell-to-cell
communication 102. Recent studies have identified the ability of B-ALL cell to take up
exosomes secreted from stromal cells in the microenvironement103. Therefore, we
expect B-ALL cells in the microenvironment to be capable of taking up secreted
neutrophilic exosomes. Further studies would first include isolating exosomes secreted
from healthy PMNs and identifying the presence of NE and P3 in secreted vesicles. If
both are present, it would then be determined whether malignant cells can take them
up. However, uptake does not mean that NE and P3 would be processed for crosspresentation to occur. We would therefore identify the mechanisms of processing and
whether this would lead to antigen presentation.
These findings provide evidence that PR1 would be an effective target in
treatment of B-ALL patients. Further, identifying the source of NE and P3 uptake in the
bone marrow microenvironment would be beneficial in understanding and enhancing
NE and P3 uptake. Data further expanded the use of 8F4 in non-myeloid tumor types,
and identified cross-presentation as the mechanism rendering them susceptible.
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